Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Lymphomas: A Practical Guide for Pharmacists

Program Description

Lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), often becomes relapsed/refractory despite standard chemotherapy or targeted therapies and requires novel therapeutic approaches. Bispecific antibodies (BsAbs) represent a significant advancement, yet their complex administration, potential for serious adverse effects, and the increasing trend toward community-based administration pose significant challenges for oncology pharmacists. As BsAbs gain approval for earlier lines of therapy and more indications, their use is shifting to community pharmacies and clinics. For these reasons, it is pharmacists within community cancer settings who frequently serve as the link between the oncology clinic and local hospitals and support the coordinated care of patients with DLBCL and FL. This webinar will equip oncology pharmacists to navigate the evolving landscape of BsAbs by exploring recent FDA approvals and clinical evidence for agents across different lines of therapy. Practical approaches for personalizing treatment plans, using tools for toxicity monitoring, implementing infection prophylaxis protocols, and leading comprehensive patient and caregiver education to ensure safe and effective use of BsAbs will be emphasized.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: December 19, 2025
Expiration date: December 19, 2026
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the evolving role of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory (R/R) lymphomas, including recent FDA approvals, expanded indications, and updates to clinical guidelines.
• Optimize personalized treatment plans for patients with lymphoma involving the application of BsAbs.
• Analyze evidence-based approaches for monitoring, prevention, and management of common and serious AEs associated with BsAbs.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-415-H01-P. The activity is available for CE credit through December 19, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

James A. Davis PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: BMS, Janssen, GSK

Speakers Bureau: Janssen

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms